27 January 2020 | News
In response to recent Chinese government pronouncements signaling a large expansion of the role and use of TCMPs in the Chinese health care system
Image Credit: shuttershock.com
China SXT Pharmaceuticals, a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs") has announced that it will be increasing its production of its entire TCM product line, in response to recent Chinese government pronouncements signaling a large expansion of the role and use of TCMPs in the Chinese health care system.
The initial directive, promulgated by the State Council of the People’s Republic of China, contained general priorities in medical and healthcare system reform. This was followed by guidelines issued by the State Council together with the Central Committee of the Communist Party of China, which specifically called for all community health service centers and township clinics in the country to offer TCM services by 2022, including TCM-based solutions for the prevention and treatment of, and rehabilitation from, illness and disease. The guidelines were later reinforced with an announcement by the State Council on October 26, 2019.
After reviewing the Chinese authorities’ guidelines, which further directed that existing TCM hospitals should increase their service capacity, China SXT has begun instituting plans to take advantage of the opportunity presented through an immediate ramp up in production of its entire TCM line, including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements.
Mr. Feng Zhou, Chief Executive Officer and Director of China SXT, commented, "These new guidelines have provided us with both the impetus and the reassurance we needed to embark on our next phase of expansion, as we move forward to our stated goal of becoming one of the world’s leading specialty pharmaceutical company in TCMPs,” adding that “equally important to us is that with the increase in production came improvements in our production systems and technologies, which we have been able to fund thus far through existing cashflows.”